Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06625320 · ClinicalTrials.gov registry record · Phase 3

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

A Phase 3 study of Pancreatic Cancer and PDAC - Pancreatic Ductal Adenocarcinoma, sponsored by Revolution Medicines.

Active
Registry status
Phase 3
Development phase
501
Enrollment target
20
Study locations

NCT06625320 is a Phase 3 study of Pancreatic Cancer and PDAC - Pancreatic Ductal Adenocarcinoma that is active but no longer recruiting, run by Revolution Medicines. The registered enrollment target is 501 participants, above the 391-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (28% higher). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06625320, a Phase 3 study of Pancreatic Cancer and PDAC - Pancreatic Ductal Adenocarcinoma, is active but no longer recruiting, sponsored by Revolution Medicines.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
501 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.

Conditions Studied

Pancreatic Cancer PDAC - Pancreatic Ductal Adenocarcinoma PDAC

Interventions

  • DRUG Gemcitabine
  • DRUG Irinotecan
  • DRUG nab-paclitaxel
  • DRUG RMC-6236
  • DRUG Liposomal irinotecan

Study Locations (20)

California

  • City of Hope-Duarte - Duarte
  • Cedars-Sinai Medical Center - Los Angeles
  • UCLA - Los Angeles
  • UC San Diego Health Moores Cancer Center - San Diego
  • Mission Hall UCSF - San Francisco

Florida

  • Mayo Clinic Cancer Center - Florida - Jacksonville
  • University of Miami Sylvester Comprehensive Cancer Center - Miami
  • Cancer Care Centers of Brevard Inc - Palm Bay
  • Moffitt Cancer Center - Tampa

Arizona

  • Banner MD Anderson Cancer Center - Gilbert
  • Mayo Clinic Cancer Center - Phoenix - Phoenix

Michigan

  • University of Michigan - Ann Arbor
  • Karmanos Cancer Institute - Detroit

Colorado

  • Rocky Mountain Cancer - Aurora

Hawaii

  • The Queen's Medical Center - Honolulu

Illinois

  • The University of Chicago Medical Center - Chicago

Maryland

  • Johns Hopkins - Baltimore

Trial Details

FieldValue
Enrollment Target 501 participants
Start Date 2024-10-16
Est. Completion 2027-12
Phase Phase 3

Sponsor

Revolution Medicines

16 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06625320

The ClinicalTrials.gov registry entry for NCT06625320 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 501 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 391-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (28% higher). The listed sponsor is Revolution Medicines, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 5 interventions - of which Gemcitabine is the first listed.

NCT06625320 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT06625320 about?

NCT06625320 is a clinical study titled "Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)". The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.

What is the current status of trial NCT06625320?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 501 participants. The study started on 2024-10-16. Estimated completion is 2027-12.

What conditions does trial NCT06625320 study?

This clinical trial studies the following conditions: Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, PDAC.

What interventions are being tested in trial NCT06625320?

The interventions under investigation include: Gemcitabine (DRUG), Irinotecan (DRUG), nab-paclitaxel (DRUG), RMC-6236 (DRUG), Liposomal irinotecan (DRUG).

Who is sponsoring clinical trial NCT06625320?

This trial is sponsored by Revolution Medicines, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06625320 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pancreatic Cancer

All registered trials for this condition

PDAC - Pancreatic Ductal Adenocarcinoma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.